Developmental Research Program

项目总结 纽约大学黑色素瘤孢子发育研究计划(DRP)的总体目标是支持飞行员 最大限度地利用黑色素瘤新研究机会并帮助招聘的项目 负责翻译研究的助理教授或更高级别的资深癌症研究人员 黑色素瘤。DRP专注于并将选择创新的和有前途的翻译研究项目 治疗黑色素瘤，并将监测其进展以确保达到目标。DRP的主任是Iannis博士 艾芬蒂斯，纽约大学病理学系主任，一位享誉国际的调查员，他带来了 在导师的指导和新兴的转化性黑色素瘤研究成功方面取得了成就。他会的 与内部评估小组和孢子PD/PI合作，确定和支持选定的飞行员 具有非凡翻译潜力的研究。纽约大学黑色素瘤孢子DRP将支持UP项目 到2年，使获奖者能够充分探索翻译黑色素瘤的新主题的潜力 研究。聚焦创新，发改委将支持“高风险、高回报”发展 研究黑色素瘤并鼓励提出新的筛查、诊断、预后、 黑色素瘤的预测和治疗。DRP将监督所有项目的进度和选定的获奖者 获得资金，以确保实现目标，并确保DRP项目可能处于强有力的地位，以取代任何 孢子项目要么没有达到其翻译研究目标，要么在奖项结束前完成 句号。 DRP在主题和程序上与纽约大学较大的黑色素瘤孢子和 认识到孢子生长的一个关键组成部分是继续支持和发展 关于黑色素瘤的新研究，特别是在改善黑色素瘤个性化管理方面 病人。纽约大学朗格尼健康中心(NYULH)和纽约大学珀尔穆特癌症中心(PCC)一直以来 使用各种试点资助机制来支持有前景的黑色素瘤预后的新方法，临床 管理和治疗。

PROJECT SUMMARY The overall goal of the NYU Melanoma SPORE Developmental Research Program (DRP) is to support pilot projects that take maximum advantage of new research opportunities in melanoma and aid in recruiting established cancer investigators at the level of Assistant Professor or higher to the translational study of melanoma. The DRP focuses on and will select innovative and promising translational research projects in melanoma, and will monitor their progress to ensure that goals are met. The Director of the DRP is Dr. Iannis Aifantis, the Chair of the NYU Department of Pathology and an internationally regarded investigator who brings an accomplished track record of mentorship and emerging translational melanoma research success. He will work together with an internal evaluation panel and the SPORE PD/PIs to identify and support selected pilot studies with exceptional translational potential. The NYU Melanoma SPORE DRP will support projects for up to 2 years, enabling awardees to adequately explore the potential of novel topics in translational melanoma research. Focusing on innovation, the DRP will support the development of “high-risk, high-reward” investigations in melanoma and encourage proposals for novel approaches to screening, diagnosis, prognosis, prediction, and treatment of melanoma. The DRP will monitor the progress of all projects and awardees chosen for funding to ensure that goals are met and that DRP projects may be strongly positioned to replace any SPORE project either not meeting its translational research goals or completed prior to the close of the award period. The DRP is highly integrated thematically and programmatically with the larger NYU Melanoma SPORE and recognizes that a key component to the growth of the SPORE is the continued support and development of novel investigations in melanoma, specifically in the area of improved personalized management of melanoma patients. Both NYU Langone Health (NYULH) and the NYU Perlmutter Cancer Center (PCC) have consistently used various pilot funding mechanisms to support promising novel approaches to melanoma prognosis, clinical management, and treatment.